DK3377176T3 - Fremgangsmåde til behandling af patienter, der får administreret rivaroxaban sammen med verapamil - Google Patents

Fremgangsmåde til behandling af patienter, der får administreret rivaroxaban sammen med verapamil Download PDF

Info

Publication number
DK3377176T3
DK3377176T3 DK17757069.4T DK17757069T DK3377176T3 DK 3377176 T3 DK3377176 T3 DK 3377176T3 DK 17757069 T DK17757069 T DK 17757069T DK 3377176 T3 DK3377176 T3 DK 3377176T3
Authority
DK
Denmark
Prior art keywords
rivaroxaban
administrated
verapamil
patients
procedure
Prior art date
Application number
DK17757069.4T
Other languages
English (en)
Inventor
Christina Chow
Maulik Patel
Sundar Srinivasan
Original Assignee
Morgandane Scient Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morgandane Scient Llc filed Critical Morgandane Scient Llc
Application granted granted Critical
Publication of DK3377176T3 publication Critical patent/DK3377176T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
DK17757069.4T 2016-02-23 2017-02-21 Fremgangsmåde til behandling af patienter, der får administreret rivaroxaban sammen med verapamil DK3377176T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662298555P 2016-02-23 2016-02-23
PCT/US2017/018727 WO2017147074A1 (en) 2016-02-23 2017-02-21 METHOD OF TREATING PATIENTS COADMINISTERED A FACTOR Xa INHIBITOR AND VERAPAMIL

Publications (1)

Publication Number Publication Date
DK3377176T3 true DK3377176T3 (da) 2022-01-10

Family

ID=59630469

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17757069.4T DK3377176T3 (da) 2016-02-23 2017-02-21 Fremgangsmåde til behandling af patienter, der får administreret rivaroxaban sammen med verapamil

Country Status (15)

Country Link
US (6) US20170239260A1 (da)
EP (3) EP4134131A1 (da)
CA (1) CA3010726A1 (da)
CY (1) CY1125307T1 (da)
DK (1) DK3377176T3 (da)
ES (1) ES2903359T3 (da)
HR (1) HRP20211946T1 (da)
HU (1) HUE056739T2 (da)
LT (1) LT3377176T (da)
PL (1) PL3377176T3 (da)
PT (1) PT3377176T (da)
RS (1) RS62797B1 (da)
SI (1) SI3377176T1 (da)
SM (1) SMT202200012T1 (da)
WO (1) WO2017147074A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722486B2 (en) 2018-08-13 2020-07-28 Morgandane Scientific, LLC Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
RU2743938C1 (ru) * 2020-03-05 2021-03-01 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации Способ профилактики тромбоза зоны реконструкции после протезирования системы воротной вены при раке поджелудочной железы
RU2759129C1 (ru) * 2021-03-01 2021-11-09 федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации Способ профилактики послеоперационной тромбоэмболии легочных артерий при опухолевом тромбозе нижней полой вены
WO2022235779A1 (en) * 2021-05-05 2022-11-10 Angion Biomedica Corp. Methods of administering terevalefim
US20250177407A1 (en) * 2023-12-04 2025-06-05 Closed Loop Medicine Ltd. Rivaroxaban Dosing

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2278712A (en) 1940-11-29 1942-04-07 Transit Res Corp Superresilient wheel
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR082803A1 (es) * 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida

Also Published As

Publication number Publication date
US20190167693A1 (en) 2019-06-06
US20210338682A1 (en) 2021-11-04
CA3010726A1 (en) 2017-08-31
HRP20211946T1 (hr) 2022-03-18
SMT202200012T1 (it) 2022-03-21
LT3377176T (lt) 2022-01-25
US20180311256A1 (en) 2018-11-01
EP3377176A1 (en) 2018-09-26
CY1125307T1 (el) 2024-02-16
PL3377176T3 (pl) 2022-02-28
US20190142839A1 (en) 2019-05-16
SI3377176T1 (sl) 2022-03-31
HUE056739T2 (hu) 2022-03-28
EP3377176B1 (en) 2021-10-20
ES2903359T3 (es) 2022-04-01
EP3978072A1 (en) 2022-04-06
EP4134131A1 (en) 2023-02-15
RS62797B1 (sr) 2022-02-28
EP3377176A4 (en) 2019-07-31
WO2017147074A1 (en) 2017-08-31
PT3377176T (pt) 2022-01-13
US20170239260A1 (en) 2017-08-24
US20240252501A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
DK3448426T3 (da) Fremgangsmåder til behandling af patienter med familiær hyperkolesterolæmi
DK3340981T3 (da) Aryl, heteroaryl og heterocykliske forbindelser til behandling af medicinske forstyrrelser
DK3173092T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3439635T3 (da) Formuleringer til behandling af fast tumor
DK3411393T3 (da) Administration af manipulerede t-celler til behandling af cancere i centralnervesystemet
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
DK3383436T3 (da) Forbedret fremgangsmåde til fremstilling af indocyaningrønt
DK3624796T3 (da) Pyrrolopyridin.anilinforbindelser til behandling af hudlidelse
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
EP3445750A4 (en) THERAPEUTIC COMPOUNDS
DK3294283T3 (da) Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens
DK3324824T3 (da) Fremgangsmåde til behandling af binokulare dysfunktioner
DK3512517T3 (da) Anvendelse af pridopidin til behandling af angst og depression
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3484423T3 (da) Anordning til hypertermisk behandling af kløe
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
IL257355B (en) Selection of patients for combination therapy